- In December 2021, Acadia Pharmaceuticals Inc. announced the positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years suffering from Rett syndrome. Trofinetide is an experimental medication. It's a new synthetic analogue of IGF-1's aminoterminal tripeptide that could help with Rett syndrome's fundamental symptoms by lowering neuroinflammation and supporting synaptic function. Trofinetide is expected to promote synaptic maturation and help patients overcome the synaptic and neuronal immaturities that are common in Rett syndrome
